MassDevice.com looked at some of the most talked-about medical device companies, based on trends in Google searches for the last 30 days.
During the last month the medtech titans were flush with news from conferences, court rooms and Wall Street.
Minnesota giant Medtronic (NYSE:MDT) hit new highs after issuing its Q4 2013 earnings report, unveiled updates from trials of its renal denervation and TAVI devices and sparred with rivals over patents and batteries.
Johnson & Johnson (NYSE:JNJ) jumped into a prominent seat on the list with stories driven largely by the ongoing metal-on-metal hip lawsuits (and a failure to appeal a $8.3M verdict) as well as by some legal battles over copyrights and spine patents.
Covidien (NYSE:COV) slid to 3rd place in May with stolen merchandise and new financials ahead of a pharma spinout. Boston Scientific (NYSE:BSX) remained 4th with a dramatic overseas legal battle with OrbusNeich (which asked police to seize BoSci’s stents) and a patent tussle with Medtronic that’s headed for the Supreme Court.
St. Jude Medical (NYSE:STJ) closed out the top 5 with R&D developments in renal denervation and multi-point pacing, and some more good news for its Durata devices.
- Diabetes: Medtronic partners with China to develop care for Type I diabetics
- Details emerge on Medtronic’s spinal business layoffs
- Medtronic warns on wire damage risk with deep-brain stimulation implants
- Medtronic touts FDA win for cost-saving heart rhythm implants
- Docs defend Medtronic in brain implant recall, analysts say it’s no “big deal”
- Medtech titans Medtronic, Boston Scientific spar over CRM battery life
- Medtronic asks Supreme Court to overturn $74M loss against Edwards Lifesciences
- Medtronic’s Ishrak: Europe slow to adopt renal denervation
- Medtronic to seek expanded CRT indication on biventricular pacing data
- Elixir goes head-to-head against Medtronic with its DESyne Nx DES study
- Supreme Court to hear Medtronic’s appeal of Boston Scientific’s CRM patent win
- Medtronic touts European win for Export Advance aspiration catheter
- Medtronic’s Q4, 2013 profits slide
- Medtronic: We’re about 2/3 through restructuring plan, layoffs
- Medtronic’s renal denervation looks good in the real world
- Medtronic hits 52-week high on Q4, FY2013 results
- Medtronic’s CoreValve is a cost-effective option, U.K. researchers say
- European regulators green-light valve-in-valve procedures
- Medtronic moving forward with its renal denervation study
- Pediatric ICD study finds higher rate of failure for Sprint Fidelis leads in kids
- EuroZone OKs Medtronic’s CoreValve for valve-in-valve implants
- Medtronic’s Endurant II AUI stent graft wins FDA approval
- Bellwether federal trial against DePuy delayed
- J&J’s Ethicon Endo-Surgery wins FDA approval for Sedasys computer-assisted anesthesia device
- Another recall for Johnson & Johnson Down Under
- Globus Medical sues J&J’s DePuy Synthes unit over spine implant patent
- Johnson & Johnson’s DePuy will stop selling metal-on-metal implants
- Can Johnson & Johnson fire on all cylinders again?
- Judge orders J&J’s DePuy Orthopaedics to produce compliance reports
- Biosense Webster launches Afib ablation study for nMARQ system
- J&J sues Shasta Technologies for logo infringement
- Johnson and Johnson executive splits for the corner office at Itamar Medical
- J&J’s DePuy can’t dodge $8.3M metal hip implant verdict
- J&J’s Biosense Webster can’t keep ex-reps from selling for St. Jude
- FDA gives Covidien recall highest-risk label
- Meet the ‘New Covidien’
- FDA warns of stolen, unsterilized Covidien surgical staples
- New communications chief at Covidien
- Covidien restates Q2 financials ahead of pharma spinout
- Chest docs include Covidien’s superDimension lung biopsy device in guidelines
- Covidien touts positive study data from Barrx ablation system
- Covidien launches its new respiratory monitoring device
- FDA clears Covidien’s Nellcor pulse oximeter for pediatric care
- Masimo throws down the gauntlet with $1M challenge against Covidien
- Boston Scientific leads $9.7M Series B round for Channel Medsystems
- Boston Scientific wraps up 1st human trial for IntellaTip ablation catheter
- Medtech titans Medtronic, Boston Scientific spar over CRM battery life
- OrbusNeich blocks German imports of Boston Scientific’s stents
- Boston Scientific hits 52-week high on Watchman trial results
- Boston Scientific logs another 52-week high on CE Mark for Rhythmia heart mapping system
- Boston Scientific may finally be on the right path again
- Boston Scientific touts battery life data
- German court issues 2nd injunction against Boston Scientific in OrbusNeich stent patent spat
- Boston Scientific hits new 52-week high on WallFlex stent trial launch
- Vascular Solutions CEO: Boston Scientific’s alleged patent infringement ‘blatant’
- Supreme Court to hear Medtronic’s appeal of Boston Scientific’s CRM patent win
- Boston Scientific denies OrbusNeich accusations
- Boston Scientific’s Lotus TAVI bests rivals with less leakage
- Volcano, Boston Scientific team up for accurate stent placement study
- Podcast: Boston Scientific CEO Michael Mahoney at the MassDevice Big 100 East
- Boston Scientific’s deep-brain stimulation imaging guide makes the cut in Europe
- Boston Scientific’s renal denervation looking good at 6 months
- Boston Scientific legal update: Ups and downs in tussles with Iraq, OrbusNeich and the feds
- Boston Scientific’s 5-part recipe for success
- Abbott, Boston Scientific pay almost no taxes in Ireland despite billions in profits
- St. Jude Medical launches new study of next-gen multi-point cardiac pacing
- U.S. Justice Dept. closes St. Jude Riata probe
- Heart failure doesn’t worsen with St. Jude’s recalled QuickSite CRT leads
- St. Jude Medical touts independent safety data for next-gen Durata leads
- St. Jude’s new CE Marked defibrillators aim to reduce insulation abrasion
- St. Jude Medical kicks off renal denervation device study
- St. Jude Medical wins EU green light for Ilumien Optis
- St. Jude’s EnligHTN device shows promising 1-year trial results
- The bulls may have run a little too far with St. Jude Medical
- J&J’s Biosense Webster can’t keep ex-reps from selling for St. Jude
